Forbes -
4 Oct 2021 15:30

The stock price of Eli Lilly has seen a decline of 11% over the last twenty-one trading days. There are a couple of factors that fueled this decline. First, earlier in September, Biogen stated that the launch of Aduhelm - Biogen's treatment for Alzheimer's disease - was slower than anticipated...
Share this Article